Arbutus Biopharma Corp Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration
Arbutus Biopharma Corp (ABUS) had Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration of $11.70 million as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration · last filed 2026-03-23
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $11.70M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $11.70M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $11.70M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $11.70M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration | Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration as first filed |
|---|---|---|
| 2025-12-31 | $11.70M 10-K · filed 2026-03-23 | |
| 2024-12-31 | $11.70M 10-K · filed 2026-03-23 | |
| 2023-12-31 | $11.70M 10-K · filed 2025-03-27 | |
| 2022-12-31 | $11.70M 10-K · filed 2024-03-05 | |
| 2021-12-31 | $11.70M 10-K · filed 2023-03-02 | |
| 2020-12-31 | $11.70M 10-K · filed 2022-03-03 | |
| 2019-12-31 | $11.70M 10-K · filed 2021-03-04 | $11.73M 10-K · filed 2020-03-05 |
| 2018-12-31 | $11.04M 10-K · filed 2020-03-05 | |
| 2017-12-31 | $13.72M 10-K · filed 2019-03-07 | |
| 2016-12-31 | $14.62M 10-K · filed 2018-03-16 | |
| 2015-12-31 | $17.23M 10-K · filed 2016-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |